About Cellular Biomedicine Group
Cellular Biomedicine Group is a company based in Cupertino (United States) founded in 2001.. Cellular Biomedicine Group has raised $120 million across 6 funding rounds from investors including Astrazeneca, Sequoia Capital and Yunfeng Capital. Cellular Biomedicine Group operates in a competitive market with competitors including Mesoblast, RoosterBio, SanBio, BrainStorm Cell and Osiris, among others.
- Headquarter Cupertino, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cellular Biomedicine Group, Inc.
-
Annual Revenue
$00as on Apr 11, 2014
-
Net Profit
-
EBITDA
-
Total Equity Funding
$120 M (USD)
in 6 rounds
-
Latest Funding Round
$120 M (USD), Series A
Sep 30, 2021
-
Investors
Astrazeneca
& 5 more
-
Employee Count
Employee Count
-
Acquired by
(Aug 12, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Cellular Biomedicine Group
Cellular Biomedicine Group has successfully raised a total of $120M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $120 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series A — $120.0M
-
First Round
First Round
(26 Jul 2013)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Series A - Cellular Biomedicine Group | Valuation | Sequoia Capital China , Yunfeng Capital | |
| Feb, 2018 | Amount | Post-IPO - Cellular Biomedicine Group | Valuation |
investors |
|
| Feb, 2016 | Amount | Post-IPO - Cellular Biomedicine Group | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cellular Biomedicine Group
Cellular Biomedicine Group has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Sequoia Capital and Yunfeng Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed by Yunfeng Capital in China.
|
Founded Year | Domain | Location | |
|
Sovereign wealth is managed and private equity investments are facilitated.
|
Founded Year | Domain | Location | |
|
TF Capital is engaged in biotech investment and strategic support.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cellular Biomedicine Group
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cellular Biomedicine Group
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cellular Biomedicine Group Comparisons
Competitors of Cellular Biomedicine Group
Cellular Biomedicine Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mesoblast, RoosterBio, SanBio, BrainStorm Cell and Osiris, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
|
| domain | founded_year | HQ Location |
Developer of human mesenchymal stem cells and extracellular vesicles
|
|
| domain | founded_year | HQ Location |
Regenerative cell medicines for neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD
|
|
| domain | founded_year | HQ Location |
Stem cell-based regenerative medicines are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Mesenchymal stem cells are developed for therapeutics using proprietary methods.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cellular Biomedicine Group
Frequently Asked Questions about Cellular Biomedicine Group
When was Cellular Biomedicine Group founded?
Cellular Biomedicine Group was founded in 2001 and raised its 1st funding round 12 years after it was founded.
Where is Cellular Biomedicine Group located?
Cellular Biomedicine Group is headquartered in Cupertino, United States. It is registered at Cupertino, California, United States.
Is Cellular Biomedicine Group a funded company?
Cellular Biomedicine Group is a funded company, having raised a total of $120M across 6 funding rounds to date. The company's 1st funding round was a Post-IPO of $5M, raised on Jul 26, 2013.
What does Cellular Biomedicine Group do?
Cellular Biomedicine is developing cellular therapeutics for cancer, orthopaedic disorders, and COPD. Its stem cell drug pipeline includes AlloJoin, an off-the-shelf allogeneic adipose-derived mesenchymal progenitor cell (haMPC) for Knee Osteoarthritis (KOA) (Phase 23), ReJoin-a human adipose-derived mesenchymal progenitor cell (haMPC) therapy for KOA (Phase 1), and Human Adipose-Derived Mesenchymal Progenitor Cells (haMPC) for Chronic Obstructive Pulmonary Disease (COPD) (Preclinical). Its immuno-oncology pipeline includes CAR-T therapies for Diffuse Large B-Cell Lymphoma (Phase 1)-Acute Lymphoblastic Leukemia (Phase 1).
Who are the top competitors of Cellular Biomedicine Group?
Cellular Biomedicine Group's top competitors include RoosterBio, Mesoblast and SanBio.
Who are Cellular Biomedicine Group's investors?
Cellular Biomedicine Group has 6 investors. Key investors include Astrazeneca, Sequoia Capital, Yunfeng Capital, GIC, and TF Capital.